Conference Coverage (12th World AIDS)

Avipox AIDS Vaccine Elicits Durable Anti-HIV CTLs

Published in AIDS Weekly, August 24th, 1998

More than half of the volunteers who received a candidate AIDS vaccine developed durable, HIV specific cytotoxic T-lymphocyte (CTL) responses.

The vaccine is a canarypox virus engineered to express HIV genes. The virus is capable only of a single round of expression in human cells and has proven safe in earlier human tests.

"We are having very good, durable CTL," said Thomas Evans of the AIDS Vaccine Evaluation Group (AVEG). "At two years it looks like 50 percent [of subjects] will be positive for [CTL specific for] HIV-1 Env or Gag."

Evans presented the data to the 12th World AIDS Conference, held June 28-July 3, 1998, in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1998-08-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry